MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis

被引：0
|
作者：
Defeng Hu [1 ]
Yixuan Hu [2 ]
Shipeng Lei [1 ]
Dongdong Wu [3 ]
Yubo Wang [1 ]
机构：
[1] Chongqing University Jiangjin Hospital,Department of Respiratory and Critical Care Medicine
[2] Army Medical University,Basic Medicine School
[3] Army Medical University,Department of Information, Daping Hospital
来源：
BMC Cancer | / 25卷 / 1期
关键词：
D O I：
10.1186/s12885-025-14145-5
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] EGFR mutations and EGFR tyrosine kinase inhibitors
    Torri, Valter
    Broggini, Massimo
    Garassino, Marina Chiara
    LANCET ONCOLOGY, 2015, 16 (07): : 746 - 748
  • [2] Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
    Baldacci, Simon
    Mazieres, Julien
    Tomasini, Pascale
    Girard, Nicolas
    Guisier, Florian
    Audigier-Valette, Clarisse
    Monnet, Isabelle
    Wislez, Marie
    Perol, Maurice
    Do, Pascal
    Dansin, Eric
    Leduc, Charlotte
    Leprieur, Etienne Giroux
    Moro-Sibilot, Denis
    Tulasne, David
    Kherrouche, Zoulika
    Labreuche, Julien
    Cortot, Alexis B.
    ONCOTARGET, 2017, 8 (62) : 105103 - 105114
  • [3] Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
    Zheng, Haosheng
    Qin, Xianyu
    Zheng, Yuzhen
    Yang, Xingping
    Tan, Jian
    Cai, Weijie
    He, Shiyun
    Liao, Hongying
    FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [4] Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Helena Linardou
    Issa J. Dahabreh
    Dimitrios Bafaloukos
    Paris Kosmidis
    Samuel Murray
    Nature Reviews Clinical Oncology, 2009, 6 : 352 - 366
  • [5] Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Linardou, Helena
    Dahabreh, Issa J.
    Bafaloukos, Dimitrios
    Kosmidis, Paris
    Murray, Samuel
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (06) : 352 - 366
  • [6] Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC
    Jacobs, Ryan
    Fong, Jason
    Bomgarden, Ryan
    Rogers, John
    Puri, Neelu
    CANCER RESEARCH, 2012, 72
  • [7] MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
    Kubo, Takafumi
    Yamamoto, Hiromasa
    Lockwood, William W.
    Valencia, Ilse
    Sob, Junichi
    Peyton, Michael
    Jida, Masaru
    Otani, Hiroki
    Fujii, Tetsuva
    Ouchida, Mamoru
    Takigawa, Nagio
    Kiura, Katsuyuki
    Shimizu, Kenji
    Date, Hiroshi
    Minna, John D.
    Varella-Garcia, Marileila
    Lam, Wan L.
    Gazdar, Adi F.
    Toyooka, Shinichi
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (08) : 1778 - 1784
  • [8] MET tyrosine kinase inhibitors
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) : 469 - 469
  • [9] Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
    Kobayashi, Susumu
    Canepa, Hannah M.
    Bailey, Alexandra S.
    Nakayama, Sohei
    Yamaguchi, Norihiro
    Goldstein, Michael A.
    Huberman, Mark S.
    Costa, Daniel B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : 118 - 122
  • [10] Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
    Zhe Zhang
    Sen Yang
    Qiming Wang
    Biomarker Research, 7
12345